Published in Int J Gynecol Cancer on August 01, 2011
Optimizing working-space in laparoscopy: measuring the effect of mechanical bowel preparation in a porcine model. Surg Endosc (2013) 0.81
Predisposing factors for postoperative nausea and vomiting in gynecologic tumor patients. Support Care Cancer (2016) 0.76
Letter to the editor on "Preoperative bowel preparation in gynecologic oncology: a review of practice and an impetus to change" by Wells et al, Int J Gyn Cancer 2011; 21(6):1135-1142. Int J Gynecol Cancer (2012) 0.75
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can (2007) 2.09
Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol (2012) 1.86
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A (2012) 1.51
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol (2013) 1.47
Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol (2007) 1.37
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol (2013) 1.36
Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res (2006) 1.23
The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol (2012) 1.23
Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol (2008) 1.20
Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab (2004) 1.19
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One (2011) 1.18
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet (2006) 1.17
Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res (2010) 1.14
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol (2005) 1.13
Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol (2006) 1.11
The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle (2013) 1.08
No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result. Cancer Epidemiol Biomarkers Prev (2005) 1.04
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol (2008) 1.00
Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol (2006) 0.99
Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol (2011) 0.98
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget (2014) 0.98
Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet (2005) 0.94
Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol (2015) 0.93
Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab (2010) 0.93
The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res (2004) 0.92
Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab (2010) 0.91
Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol (2008) 0.90
Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer (2006) 0.90
Value of sentinel node mapping in cancer of the cervix. Gynecol Oncol (2011) 0.90
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol (2011) 0.89
Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecol Oncol (2012) 0.89
Upstaging based solely on positive peritoneal washing does not affect outcome in endometrial cancer. Mod Pathol (2005) 0.88
Mixed ovarian large cell neuroendocrine carcinoma, mucinous adenocarcinoma, and teratoma: a report of two cases and review of the literature. Pathol Res Pract (2009) 0.87
Should ovaries be removed or not in (early-stage) adenocarcinoma of the uterine cervix: a review. Gynecol Oncol (2014) 0.86
No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. Genet Test (2006) 0.86
Primary villoglandular adenocarcinoma of cloacogenic origin of the vulva. Hum Pathol (2004) 0.86
Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol (2013) 0.85
Mucinous ovarian tumors of Mullerian-type: an analysis of 17 cases including borderline tumors and intraepithelial, microinvasive, and invasive carcinomas. Int J Gynecol Pathol (2005) 0.85
Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population. J Genet Couns (2008) 0.85
Metastatic gastrointestinal tract cancer presenting as ovarian carcinoma. J Obstet Gynaecol Can (2003) 0.84
SOGC–GOC–SCC Joint Policy Statement. No. 255, March 2011. Cervical cancer prevention in low-resource settings. J Obstet Gynaecol Can (2011) 0.84
Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One (2011) 0.84
Ovarian thecoma associated with a large quantity of ascites and elevated serum CA 125 and CA 15-3. J Obstet Gynaecol Can (2002) 0.84
Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population. Int J Gynecol Cancer (2012) 0.84
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer (2014) 0.83
Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. Eur J Hum Genet (2011) 0.82
Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol (2009) 0.82
The role of adjuvant therapy in endometrial cancer. J Obstet Gynaecol Can (2013) 0.81
Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. Biopreserv Biobank (2013) 0.81
Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. PLoS One (2013) 0.81
Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol (2012) 0.81
Primitive clear cell carcinoma of the vagina treated conservatively. J Obstet Gynaecol Can (2009) 0.81
The significance of surgical staging in intermediate-risk endometrial cancer. Gynecol Oncol (2011) 0.81
Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev (2007) 0.80
Epidemiology and investigations for suspected endometrial cancer. J Obstet Gynaecol Can (2013) 0.80
A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. Gynecol Oncol (2002) 0.80
Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families. Fam Cancer (2007) 0.80
Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss. Am J Surg Pathol (2015) 0.79
Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges. Fam Cancer (2006) 0.79
Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families. Int J Cancer (2008) 0.79
Laparoscopically assisted vaginal radical hysterectomy. Best Pract Res Clin Obstet Gynaecol (2005) 0.79
A new alternative splice variant of BRCA1 containing an additional in-frame exon. Biochim Biophys Acta (2005) 0.79
A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol (2013) 0.79
Innovations in the treatment of invasive cervical cancer. Cancer (2003) 0.78
Negative sentinel lymph node accurately predicts negative status of pelvic lymph nodes in uterine cervix carcinoma. Gynecol Oncol (2006) 0.78
A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation. Gynecol Oncol (2012) 0.78
Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling: A Prospective Study Comparing Cytology, Frozen Section, and Core Biopsies to Full Pathologic Examination. Int J Gynecol Pathol (2015) 0.78
Indication and method of frozen section in vaginal radical trachelectomy. Int J Gynecol Pathol (2009) 0.78
Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy. J Obstet Gynaecol Can (2004) 0.78
Vaginal radical trachelectomy in the treatment of cervical cancer: the role of frozen section. Int J Gynecol Pathol (2004) 0.78
Early cervical carcinoma and fertility-sparing treatment options: MR imaging as a tool in patient selection and a follow-up modality. Radiographics (2014) 0.78
The role of surgery in endometrial cancer. J Obstet Gynaecol Can (2013) 0.77
Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. Am J Surg Pathol (2017) 0.77
Is a More Comprehensive Surgery Necessary in Patients With Uterine Serous Carcinoma? Int J Gynecol Cancer (2015) 0.76
Pilot study of radical hysterectomy versus radical trachelectomy on sexual distress. J Sex Marital Ther (2013) 0.76
Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. Int J Gynecol Cancer (2016) 0.76
Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. Int J Gynecol Cancer (2015) 0.76
HRT use among women tested for BRCA1/2 mutations following publication of the women's health initiative study results. J Obstet Gynaecol Can (2005) 0.75
Evaluation of morbidity of suction drains after retroperitoneal lymphadenectomy in gynecological tumors: a systematic literature review. Int J Gynecol Cancer (2009) 0.75
Risk-reducing Surgery in Women at Low Lifetime Risk of Developing Ovarian Carcinoma: Opportunistic Salpingectomy. Clin Obstet Gynecol (2017) 0.75
New opportunities to preserve fertility in cancer treatment. J Obstet Gynaecol Can (2002) 0.75
Place of Schauta's radical vaginal hysterectomy. Best Pract Res Clin Obstet Gynaecol (2011) 0.75
Data Set for the Reporting of Carcinomas of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Int J Gynecol Pathol (2017) 0.75
Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas. Int J Gynecol Cancer (2017) 0.75
Surgical venous thromboprophylaxis: a cross-sectional survey of canadian gynaecologic oncologists. J Obstet Gynaecol Can (2012) 0.75
p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases. Int J Gynecol Pathol (2016) 0.75
Profiling of Endogenous Estrogens, Their Precursors, and Metabolites in Endometrial Cancer Patients: Association with Risk and Relationship to Clinical Characteristics. Endocrinology (2011) 0.75
Pelvic-Floor Properties in Women Reporting Urinary Incontinence After Surgery and Radiotherapy for Endometrial Cancer. Phys Ther (2017) 0.75